Supplementary Figure S2 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy
Other
Strawser, CH; Chakraborty, B; Michaud, D; Chang, C-Y; Dent, S; Jain, V; Tolaney, SM; Weinhold, K; McAllister, SS; Miller, KE; Steadman, K ...
August 3, 2026
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Citation
APA
Chicago
ICMJE
MLA
NLM
Strawser, C. H., Chakraborty, B., Michaud, D., Chang, C.-Y., Dent, S., Jain, V., … Sammons, S. (2026). Supplementary Figure S2 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy. https://doi.org/10.1158/1078-0432.33142995
Strawser, Corinne H., Binita Chakraborty, Daniel Michaud, Ching-Yi Chang, Susan Dent, Vaibhav Jain, Sara M. Tolaney, et al. “Supplementary Figure S2 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy,” August 3, 2026. https://doi.org/10.1158/1078-0432.33142995.
Strawser CH, Chakraborty B, Michaud D, Chang C-Y, Dent S, Jain V, et al. Supplementary Figure S2 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy. 2026.
Strawser, Corinne H., et al. Supplementary Figure S2 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy. 3 Aug. 2026. Crossref, doi:10.1158/1078-0432.33142995.
Strawser CH, Chakraborty B, Michaud D, Chang C-Y, Dent S, Jain V, Tolaney SM, Weinhold K, McAllister SS, Miller KE, Steadman K, Arvai S, Hocke E, Agrawal Y, Perou CM, Goel S, McDonnell DP, Guerriero JL, Sammons S. Supplementary Figure S2 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy. 2026.